Verve to Present Interim Data from the heart-1 Phase 1b Clinical Trial of VERVE-101 in HeFH Patients at the American Heart Association's Scientific Sessions 2023
Company to hold investor event in conjunction with data presentation on November 12, 2023 BOSTON, Sept. 26, 2023 -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new...
Source: marketscreener.com